Assessment of Potential Thrombogenicity in an Animal Model of a Triple Viral Inactivated Factor IX Concentrate Manufactured in Argentina

MC, MARTINEZ; R, RODRIGUEZ; A, MARINSALDI; GR, RODRIGUEZ; HA, GUGLIELMONE; ME, BERNARDI; A, VALDOMERO; GR, CUADRA

Annals of Hematology & Oncology

Austin Publishing Group

Lugar: Irving-Texas; Año: 2021 vol. 8 p. 1343 - 1343

he risk of thromboembolism with FIX replacement therapy remainsa concern for hemophilic B patients. Previous studies from our laboratorydemonstrated that the activated factor content of the FIX Plasma Derived(FIXpd) manufactured at UNC-Hemoderivados was negligible by in vitro assay.Despite this, we considered it important to conduct studies to assess thepotential thrombogenic risk of our FIXpd concentrates using a modified stasisanimal model.FIXpd were inject doses of 100 or 200 IU F IX kg-1 and some samples weresupplemented with heparin (